Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy
Highmark's coverage determination includes testing with
"The diagnosis, treatment and care of patients with cancer is among
The Biocept Target Selector platform was used to molecularly profile the liquid biopsies of newly diagnosed, treatment-naïve advanced NSCLC patients, as well as NSCLC patients who were progressing after initial therapy. These patients also received tissue biopsy as part of the evaluation.
"This project directly supports Highmark's and AHN's mission to provide members and patients with access to the best care that is available, freeing them to be their best," said
"The positive results from our collaboration under the VITAL program further solidifies
Lung cancer is the leading cause of cancer death in the United States. The
Despite the advances of targeted therapies, a large percentage of patients may not undergo molecular profiling due to a number of practical constraints. Chief among these is the availability of tissue for molecular testing. Lung cancers are often difficult to biopsy because of their location within what is often diseased lung tissue of elderly patients. Needle biopsy is the most common technique but often does not yield enough tissue for molecular testing. Performing a second biopsy is a way of remedying this situation, but these procedures can add to risk and cost, making liquid biopsy (peripheral blood) a more feasible specimen type.
One of America's leading health insurance organizations and an independent licensee of the
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the ability of our tests to provide clinically actionable information to oncologist and their patients and the ability of
LHA Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-that-highmark-has-made-a-positive-coverage-determination-on-target-selector-liquid-biopsy-301133852.html